Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Docetaxel
Related studies linked through entity extraction aliases.
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Sequential Gemcitabine Plus Docetaxel Versus Gemcitabine Plus Mitomycin C for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- Status
- RECRUITING
- Phase
- PHASE3
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation
- Status
- RECRUITING
- Phase
- PHASE3
Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors
- Status
- RECRUITING
- Phase
- N/A
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
- Status
- RECRUITING
- Phase
- PHASE3
RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
QLC5508 in Participants With Metastatic Prostate Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
A Clinical Study of SCTB41 Combined With Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II Study Ongoing）
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- Status
- RECRUITING
- Phase
- PHASE3
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
- Status
- RECRUITING
- Phase
- PHASE2
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3